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Abstract. Background/Aim: Epithelial–mesenchymal transition
(EMT) is a process co-opted by cancer cells to invade and form
metastases. In the present study we analyzed gene expression
profiles of primary breast cancer cells in culture in order to
highlight genes related to EMT. Materials and Methods:
Microarray expression analysis of primary cells isolated from
a specimen of a patient with an infiltrating ductal carcinoma of
the breast was performed. Real-Time Quantitative Reverse
Transcription PCR (qRT-PCR) analyses validated microarray
gene expression trends. Results: Thirty-six candidate genes were
selected and used to generate a molecular network displaying
the tight relationship among them. The most significant Gene
Ontology biological processes characterizing this network were
involved in cell migration and motility. Conclusion: Our data
revealed the involvement of new genes which displayed tight
relationships among them, suggesting a molecular network in
which they could contribute to control of EMT in breast cancer.
This study may offer a basis for understanding complex
mechanisms which regulate breast cancer progression and for
designing individualized anticancer therapies. 
Breast cancer (BC) represents a highly complex group of
tumors with distinct biological behaviour, prognosis and
response to therapy (1-4). The application of gene expression
profiling technology has provided molecular classification of
BC into clinically relevant subtypes, allowing for new
approaches to predict disease recurrence and response to
different treatments, and the likelihood of metastatic
progression, and new insights into related signaling pathways
(5, 6). Indeed, microarray-based expression studies have
showed that BC is an heterogeneous disease at both the
molecular and clinical level, which comprises of at least five
subtypes with distinct gene expression patterns, associated
with different prognoses and outcomes, namely luminal A,
luminal B, HER2-overexpressing, basal-like, and normal-like
types (7-9). However, histological and molecular parameters
currently identified are still insufficient to give a reliable
prediction of the clinical outcome for individual patients.
Prediction of the metastatic potential of cancer cells is a
critical point in the treatment of BC, as well as for other types
of tumors. Nowadays, despite progress in our understanding
of cellular processes which control the metastatic process (10-
13), further characterization of the molecular mechanisms that
regulate BC progression and invasion is required in order to
improve recovery from BC.
The metastatic program of a carcinoma starts when the
neoplastic epithelial cells begin to detach from the tissue of
origin, lose their stationary phenotype and acquire motile
capability with a mesenchymal phenotype. This process, known
as epithelial-to-mesenchymal transition (EMT) which was
recognized in the past in morphogenetic steps during
development, has more recently been described as a strategy for
neoplastic cells, including BC cells, to induce invasion and
metastasis (14-18). Findings that reveal the appearance of EMT
in vivo are sometimes controversial, probably due to histological
preparation of ex vivo tissues that are not sufficiently adequate to
reveal the phenotypic and molecular signs of EMT. To
overcome these limitations, primary cell cultivation from
individual BC tissues is a relevant procedure for the in vitro
study of an ample variety of neoplastic cell features, including
metastatic traits. Recently, we described an analytical
investigation of a neoplastic primary cell population isolated
from an infiltrating ductal carcinoma (IDC) of the breast which
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revealed phenotypic traits and expression of several
mesenchymal biomarkers, such as vimentin and alpha-smooth
muscle actin (α-SMA), typical of EMT (19). Real-Time
Quantitative Reverse Transcription PCR (qRT-PCR) analysis
showed a high level of expression of multiple genes associated
with EMT, particularly TGF-β, the major inducer of the EMT in
BC (20) and some of the most representative targets of the
TGF-β signal transduction pathway, supporting the occurrence
of the process in cells of our study (19). Although some reports
describe microarray analysis investigating EMT gene signatures
in vitro by using immortalized BC cell lines (21-23), to our
knowledge only one other study has examined EMT transition
in BC primary culture by microarray analysis (24). For this
reason, this field needs to be further explored. Thus, the purpose
of this study was to analyze gene expression profile by cDNA
microarray of BC primary culture in order to highlight genes
related to EMT in BC. 
Materials and Methods
Tissue and cell cultures. An extra portion of breast IDC tissue,
unnecessary for histological diagnosis after surgery, was obtained for
this study. The patient gave her written informed consent for research
participation according to the Helsinki Declaration and the study was
approved by the Ethical Committee of the San Raffaele G. Giglio
Hospital, Cefalù (number of protocol: C.E.2012/16). The tissue was
disaggregated mechanically immediately after surgery, subjected to
enzymatic digestion with collagenase/hyaluronidase and the BC
primary cells, hereafter named simply BC cells, were isolated by
applying differential centrifugation method as previously described
(19). The BC cells were grown at 37˚C under 5% CO2-95% air
atmosphere in a humidified incubator in a selective medium of
DMEM with antibiotics supplemented with 10 mM Hepes
(Invitrogen, Carlsbad, CA, USA), 1 mg/ml bovine serum albumin
(BSA), 10 ng/ml cholera toxin, 0.5 μg/ml hydrocortisone, 5 μg/ml
insulin, 5 ng/ml epidermal growth factor (EGF), 5 μg/ml apo-
transferrin (all from Sigma-Aldrich, St. Louis, MO, USA). All gene
expression experiments were conducted when BC cells were at the
fourth growth passage. The non-tumor MCF-10A cell line was used
as mammary epithelial reference sample in line with others in vitro
BC studies (30-31) and cultured according to instructions (American
Type Culture Collection, Manassas, VA, USA). The follow-up of the
patient was not part of this study.
Whole-genome cDNA microarray expression analysis. Total RNA was
extracted from BC and MCF-10A cells using Trizol and the RNeasy
mini kit (Invitrogen) according to the manufacturer’s guidelines. RNA
concentration and purity were determined spectrophotometrically
using the Nanodrop ND-1000 (Thermo Scientific Open Biosystems,
Lafayette, CO, USA) and RNA integrity, measured as RNA integrity
number (RIN) values, was assessed using a Bioanalyzer 2100
(Agilent Technologies, Santa Clara, CA, USA). Only samples with a
maximum RIN of 10 were used for further microarray analysis. Five
hundred nanogrammes of total RNA from BC primary culture and
MCF-10A cell line were used for cRNA synthesis and labelling
according to Agilent Two-Color Microarray-Based Gene Expression
Analysis protocol. Samples were labelled with Cy5 and Cy3 dye
(Agilent Technologies). Fluorescent complementary cRNA samples
(825 ng) were hybridized onto Whole Human Genome 4×44K
microarray (Agilent Technologies) GeneChips containing all known
genes and transcripts of an entire human genome. Four replicates
were performed. Array hybridization was conducted for 17 h at 65˚C.
Images were achieved by an Agilent’s DNA Microarray Scanner with
Sure Scan high-Resolution Technology (Agilent Technologies) and
analyzed using Feature Extraction expression software (Agilent
Technologies, Santa Clara, CA, USA) that found and placed
microarray grids, rejected outlier pixels, accurately determined feature
intensities and ratios, flagged outlier features, and calculated statistical
confidences.
Statistical data analysis, background correction, normalization and
summary of expression measure were conducted with GeneSpring
GX 10.0.2 software (Agilent Technologies). Data were filtered using
two-step procedure: first the entities were filtered based on their flag
values P (present) and M (marginal) and then filtered based on their
signal intensity values, this enables very low signal values or those
that have reached saturation to be removed. Statistically significant
differences were computed by the Student’s t-test and the significance
level was set at p<0.05. The false discovery rate (FDR) was applied
as a multiple test correction method. Average gene expression values
between experimental groups were compared (on log scale) by means
of a modified ANOVA (p<0.05). Genes were identified as being
differentially expressed compared to MCF-10A cells if they had a
fold-change (FC) in expression of at least 3 and a p-value <0.05. 
The data discussed in this publication have been deposited in NCBI’s
Gene Expression Omnibus (25) and are accessible through GEO Series
accession number GSE53175 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE53175).
Microarray data are available in compliance with Minimum
Information About a Microarray Experiment (MIAME) standards.
MetaCore network analyses. Microarray data sets were also analyzed
by pathway analysis using the network building tool MetaCore
(Thomson Reuters, Philadelphia, PA, USA) consisting of millions of
relationships between proteins derived from literature publications
about proteins and small molecules (including direct protein
interaction, transcriptional regulation, binding, enzyme-substrate, and
other structural or functional relationships). Results, i.e. maps of
protein lists from the uploaded dataset, were then compared with all
the possible pathway maps for all the proteins in the database, and
the p-value was calculated based on hypergeometric distribution
probability test. The most representative networks significantly
changed were selected and analysed. 
qRT-PCR analysis. Candidate genes for qRT-PCR analysis were
chosen based on microarray results. One microgramme of total RNA
was reverse-transcribed into cDNA with SuperScriptII reverse
transcriptase according to the manufacturer’s specifications
(Invitrogen). One microlitre of cDNA (50 ng RNA equivalent) was
analyzed by real-time PCR (1 cycle 95˚C for 20 s and 40 cycles of
95˚C for 3 s, 60˚C for 30 s) in triplicate using Fast 7500 Real-Time
PCR System (Applied Biosystems). Amplification reactions were
performed in a 20 μl reaction volume containing 10 pmoles of each
primer and the Fast SYBR Green Master Mix according to the
manufacturer’s specifications (Applied Biosystems). Reaction
specificity was controlled by post-amplification melting curve
analysis. The oligonucleotide primers were selected with the Primer3
software (26-27) and tested for human specificity using NCBI
database. Primer sequences (forward and reverse) used are listed in
ANTICANCER RESEARCH 34: 2173-2184 (2014)
2174
Table I. Quantitative data, normalized versus rRNA 18S gene, were
analyzed by average of triplicates Ct (cycle threshold) according to
the 2–ΔΔct method using SDS software (Applied Biosystems). The
data shown were generated from three independent experiments and
the values are expressed relative to mRNA levels in the non-
tumuorigenic MCF-10A control cells as the mean±SD. 
STRING interaction analyses. In order to analyse potential
interactions among selected genes, STRING database of known and
predicted protein interactions was used (http://string-db.org). Direct
(physical) and indirect (functional) associations derived from four
sources: genomic context, high-throughput experiments, conserved
coexpression, and previous bibliographical knowledge, were analysed
as previously described (3).
Results
Overview of cDNA microarray gene expression. In the present
study, a two-color microarray-based gene expression analysis
(Agilent Technologies) was conducted on BC primary culture
and on MCF-10A cells used as a reference sample.
Comparative differential gene expression analysis revealed that
2,982 genes in BC cells had expression levels significantly
altered by 3-fold or greater compared to the MCF-10A
reference group: 1,553 genes were down-regulated and 1,429
were up-regulated (GSE53175). Altered transcripts were
selected and grouped according to their involvement in
specific biological pathways using integrated pathway
enrichment analysis with GeneGo MetaCore. Datasets were
loaded into the MetaCore software and the top enriched
canonical metabolic pathways were analyzed. The result of
this mapping revealed the involvement of a set of molecules
controlling specific process networks such as cytoskeleton
remodelling, cell-cycle regulation and cell adhesion in BC
primary culture in comparison with the reference sample,
processes known to have a role in EMT. In addition, lists of
differentially expressed genes were analyzed in order to search
for factors potentially involved in EMT or in BC, and new
ones to propose as new markers of interest. Thirty-six
candidate genes were selected, validated and analyzed using
PubMatrix tool (28). In this way, lists of terms such as gene
names can be assigned to a genetic, biological, or clinical
relevance in a rapid flexible systematic fashion in order to
confirm our assumptions.
EMT core list validation. Our microarray data were compared
with the ‘EMT core gene list’ recently proposed by Gröger et
al. (29). Based on cluster analysis of the gene expression
studies (GES) derived from a multitude of cell types and EMT
initiation methods, Gröger and colleagues conducted a meta-
analysis of gene expression signature defining the EMT during
cancer progression. They proposed a meaningful EMT core
gene list which describes the majority of the involved genes
across the analyzed GES. Cluster analysis of genes shared
among at least 10 datasets containing 130 genes, out of which
67 were up- and 63 were down-regulated, were further
classified into five categories: (i) cell adhesion and migration,
(ii) development, cell differentiation and proliferation, (iii)
angiogenesis and wound healing, (iv) metabolism, (v) other or
unclassified, according to single enrichment analysis. As shown
in Table II and in Figure 1, 91 (~70%) out of these 130 genes
were found to be de-regulated in BC primary culture, with the
same trend proposed by Gröger et al. (44 down-regulated genes
and 47 up-regulated). Thirty five (~27%) genes were not
included in our BC microarray dataset, while four genes (~3%)
showed an opposite expression trend with respect to Gröger et
al.’s list: Fibulin 1 (FBLN1), Latent Transforming growth
factor Beta binding Protein 1 (LTBP1) and Tissue Factor
Pathway Inhibitor (TFPI) were down-regulated, while
Follistatin (FST) was up-regulated in BC cells.
Microarray validation experiments. Firstly, we assayed mRNA
levels of the four genes showing an opposite gene expression
trend with respect to Gröger’s list: FBLN1, LTBP, TFPI and
FST genes. qRT-PCR experiments confirmed the microarray
expression trend (Tables III and IV).
Moreover, based on the microarray data set, Pubmatrix
results and MetaCore analyses, we chose 32 candidate genes
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Figure 1. Expression of genes in primary breast cancer cells compared to the Epithelial–Mesenchymal Transition core gene list of Gröger et al. (29).
and performed qRT-PCR validation experiments (Table III and
IV). Genes for validation were chosen based on two
considerations: i) factors known to be involved in EMT
transition or in BC; ii) lesser known genes involved in these
processes to propose as new molecular markers. qRT-PCR
analyses were performed in parallel with MCF-10A cells.
Genes selected were some of the most representative targets of
TGF-β signal transduction pathway, as well as cytoskeleton
and adhesion proteins, and downstream targets of this pathway
(32, 33). qRT-PCR analysis revealed an increase of mRNA
levels of genes known to be involved in mesenchymal
progression, EMT transition and in matrix modelling such as
Transforming Growth Factor beta 1 (TGFB1), Twist homolog 1
(Drosophila) (TWIST1), Vimentin (VIM), Actin, alpha 2,
smooth muscle, aorta (ACTA2), Cadherin 2, type 1, N-cadherin
(CDH2), Wingless-type MMTV integration site family,
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Table I. Primer sequences used for qRT-PCR analyses
Gene symbol Full name Forward primer 5’>3’ Reverse primer 5’>3’ Template size 
(base pairs)
ACTA2 Homo sapiens actin, alpha 2, smooth muscle, aorta gctgttttcccatccattgtg ttggtgatgatgccatgttct 148
AREG Homo sapiens amphiregulin tctccactcgctcttccaac  attgaggtccaatccagcagc 190
CD24 Homo sapiens CD24 signal transducer mRNA acatgggaacaaacagatcg tgttcaatgcaaatcaattcc 165
CDH1 Homo sapiens cadherin 1, type 1, E-cadherin (epithelial) ccaagtgcctgcttttgatga cccctacccctcaactaac 166
CDH2 Homo sapiens cadherin 2, type 1, N-cadherin (neuronal) gacaatgcccctcaagtgtt ccattaagccgagtgatggt 119
COL6A3 Homo sapiens collagen, type VI, alpha 3 caggtttgctcaggggttcata actggaccagagcaaaatggaaa 287
COL8A1 Homo sapiens collagen, type VIII, alpha 1 gccacctcaaattcctcctca cttgttcccctcgtaaactgg 252
CTGF Homo sapiens connective tissue growth factor catcttcggtggtacggtgt  gccaaacgtgtcttccagtc  259
CTSK Homo sapiens cathepsin K cccgcagtaatgacacccttt aaggcattggtcatgtagccc 258
ESRP2 Homo sapiens epithelial splicing regulatory protein 2 ccctacatgctctgcactgat aacaattgactgctgggctctt 292
FAP Homo sapiens fibroblast activation protein, alpha tacccaaaggctggagctaag ctcctgggtctttggacaatc 257
FBLN1 Homo sapiens fibulin 1 cgggcatacatgcatcaacac gaacagctgcagaggtagga 318
FGF2 Homo sapiens fibroblast growth factor 2 (basic) ctgtgatggaatggtcaggaat ttccaatttgttccgactgagtc 288
FGFBP1 Homo sapiens fibroblast growth factor binding protein 1 gtgctcagaacaaggtgaacg ttgagagagatgccctcctc 276
FN1 Homo sapiens fibronectin 1 ggaaagcatatgcagccaac ctacagtattgcgggccaga 121
FST Homo sapiens follistatin cccaactgcatcccctgtaaa gagctgcctggacagaaaaca 275
ID2 Homo sapiens inhibitor of DNA binding 2, ccgtgaggtccgttaggaaaa ggtgatgcaggctgacaatag 254
dominant negative helix-loop-helix protein 
IL6 Homo sapiens interleukin 6 (interferon, beta 2) gaggagacttgcctggtgaaa aaagctgcgcagaatgagatga 272
KRT18 Homo sapiens keratin 18 ccagtctgtggagaacgaca atctgggcttgtaggccttt 159
KRT19 Homo sapiens keratin 19 tcgagggacaggaagatcac attggcaggtcaggagaaga 158
KRT5 Homo sapiens keratin 5 tttgtctccaccacctcctc cctgggaaccaaagaatgtg 195
KRT6A Homo sapiens keratin 6A caagctcaccttccaggact gagtgtgagaggctggagga 114
KRT8 Homo sapiens keratin 8 gggaagctggtgtctgagtc ctcctgttcccagtgctacc 135
LOXL2 Homo sapiens lysyl oxidase-like 2 ctcctgctgcttctgtacc ctcgctgtgcttcctcttct 286
LTBP1 Homo sapiens latent transforming growth tcgtaccaagggcttcctgt cccggtaggcattccatcatt 280
factor beta binding protein 1  
MMP3 Homo sapiens matrix metallopeptidase cgatgcagccatttctgataag aagtgcccatattgtgccttct 302
3 (stromelysin 1, progelatinase)
MXRA5 Homo sapiens matrix-remodelling associated 5 ttcagggtgtctgtgctctg gggcaagctggagttttgaag 252
PDGFRB Homo sapiens platelet-derived growth gggtaccccaagaaggatgt gtaaggtgccaacctgcaatg 277
factor receptor, beta polypeptide 
POSTN Homo sapiens periostin, osteoblast specific factor gacacacccgtgaggaagtt accacaggaggctaactcca 281
SNAI1 Homo sapiens Snail family zinc finger 1 gcgagctgcaggactctaat ggacagagtcccagatgagc 135
TFPI Homo sapiens tissue factor pathway inhibitor gcagtctggcatctcaacaac gcctagggattgggtgaact 343
(lipoprotein-associated coagulation inhibitor) 
TGFB1 Homo sapiens transforming growth factor, beta 1 ccctggacaccaactattgc aggcagaagttggcatggta 133
THBS1 Homo sapiens thrombospondin 1 gtggaagagcatcaccctgt ggtgaggaggacactggta 269
TP63 Homo sapiens tumor protein p63 ttgcccctcctagtcatttg ctggggtggctcataaggta 110
TWIST Homo sapiens twist homolog 1 (Drosophila) gtccgcagtcttacgaggag ccagcttgagggtctgaatc 159
VIM Homo sapiens vimentin aacaaccgacactcctacaaga tggttggatacttgctggaaa 142
WNT5A Homo sapiens wingless-type MMTV gggaggaaagtccccagaaat tgaatggcacgcaattaccttgt 275
integration site family, member 5A 
member 5A (WNT5A), Matrix MetalloPeptidase 3 (MMP3),
Lysyl Oxidase-Like 2 (LOXL2), Matrix-remodelling Associated
5 (MXRA5), Collagen type VIII alpha 1 (COL8A1), Collagen
type VI alpha 3 (COL6A3), Fibronectin 1 (FN1) and connective
tissue growth factor (CTGF). Other less well-known genes
involved in these processes were also up-regulated: Platelet-
derived Growth Factor Receptor, beta polypeptide (PDGFRB),
Thrombospondin 1 (THBS1), Fibroblast Activation Protein,
alpha (FAP), interleukin-6 (IL6), Keratin-19 (KRT19), Periostin
(POSTN), Fibroblast Growth Factor 2 (FGF2), Inhibitor of
DNA binding 2 (ID2) and cathepsin K (CTSK) (Table III).
On the other hand, down-regulation was observed for some
epithelial genes and factors including also several keratins, such
as E-cadherin (CDH1), Amphiregulin (AREG), Epithelial
Splicing Regulatory Protein 2 (ESRP2), Keratin-6A (KRT6A),
Keratin-8 (KRT8), Keratin-5 (KRT5) and Keratin-18 (KRT18).
In addition, down-regulation of Fibroblast Growth Factor
Binding Protein 1 (FGFBP1), Tumor Protein p63 (TP63) and
CD24 signal transducer (CD24) mRNA levels was observed
(Table IV). All qRT-PCR validation experiments confirmed
Microarray gene expression trends as shown in Table III and IV.
Thirty-six candidate gene interactions. In order to verify
potential interactions among markers identified, we generated
a molecular network by introducing these 36 genes into
STRING, a molecular tool able to elaborate physical and
functional associations among proteins (34). Despite data
heterogeneity, Figure 2 clearly displays the tight relationships
existing among molecules, showing that 34 out of 36 genes
are closely connected in a single network. Moreover, the
STRING analysis reveals that the most significant GO
biological processes characterizing this network (Figure 3)
are involved in cell migration and motility, in agreement with
behaviour featured in tumor cells wring EMT.
Discussion
EMT is a recognized process involved in the morphogenetic
steps during development, but which is also co-opted by
various cancer cells to enable them to invade and form
metastases at distant sites.
Over the past decade, a number of GES regarding EMT
were conducted on a variety of cell types and different modes
of EMT induction. Recently, Gröger and colleagues, using a
meta-analysis of GES performed on different cell types and
treatment modalities, defined a transcriptome signature named
EMT core gene list, containing 130 well-known genes
involved in EMT, as well as new genes selected among the
multitude of GES so far described (29). All BC samples used
in those studies were immortalized BC cell lines, which are
considered well-established procedures in biomedicine for a
more complete understanding of cellular cancer process. 
A further contribution to these studies is offered by the
primary cell cultures which more tightly maintain tumor
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Table II. Microarray data for gene expression of cultured primary breast cancer cells compared with to Groger's EMT core gene list.
Down-regulated genes in Up-regulated genes in Unchanged Discordant 
accordance with accordance with (n=35) (n=4)
Groger et al. (29) (n=44) Groger et al. (29) (n=47)
Cell adhesion CD24, CDH1, ADAM12. CDH2. COL1A1, COL3A1, COL5A1, CDH11, CXCL16, ELF3,  FBLN1
and migration CXADR, DSG3, EPHA, COL6A1, COL6A3, CTGF, CYP1B1, DLC1, EPCAM, FGFR1, HAS2,
JUP, MPZL2, PLXNB1, FBLN5, FGF2, FN1, MMP2, MYL9, NR2F1, LUM, NID2, PLAT, 
S100P, SLC7A5, SYK NRP1, PPAP2B, PRKCA, RECK, SERPINE1, OVOL2, TGM2, TNFAIP6
SERPINE2, SPOCK1, TPM1, VCAN, WNT5A
Development, cell ABLIM1, ADRB2,  CDKN2C, EMP3, FBN1, IGFBP3, CA2, FGFR2, MAP7, FST, LTBP1
differentiation ALDH1A3, ANK3, BIK, IL1R1, MME, PMP22, PTX3, OCLN, PTGER2, 
and proliferation CTSL2, FGFR3, GJB3, SYNE1, TAGLN, VIM RAPGEF5, SRGN, 
IFI30, IL18, KLK7, KRT15, SULF1, TUBA1A, ZEB1
KRT17, LSR, MBP, 
PKP2, PPL, PRSS8, SPINT1
Angiogenesis – DCN, LOX – TFPI
and wound 
healing
Metabolism SORL1, ST6GALNAC2 GALNT10 ABCA1, GPX3, SLC22A4, –
SLC27A2, SMPDL3B
Others or CDS1, FAM169A, FXYD3, C5orf13, CDK14, EML1, AGR2, C10orf10, MAP1B, –
unclassified KLK10, LAD1, MTUS1, FSTL1, LTBP2, PLS1, PRRG4, SYT11, 
RHOD, SERPINB1, SLPI, RGS4, TMEM158 TMEM30B, ZHX2
TPD52L1, TSPAN1, ZNF165
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Table IV. Down-regulated genes in breast cancer primary culture
Gene symbol Entrez Gene Description Microarray qRT-PCR 
ID Fold Change Fold Change
AREG 374 Homo sapiens amphiregulin (AREG) –100.90 0.0039
CD24 100133941 Homo sapiens CD24 signal transducer Mrna –8.68 <0.0039
CDH1 999 Homo sapiens cadherin 1, type 1, –72.34 0.0026*
E-cadherin (epithelial) (CDH1)
ESRP2 80004 Homo sapiens epithelial splicing –33.05 0.0071
regulatory protein 2 (ESRP2)
FBLN1 2192 Homo sapiens fibulin 1 (FBLN1) –42.27 0.032
FGFBP1 9982 Homo sapiens fibroblast growth factor –84.19 <0.0039
binding protein 1 (FGFBP1)
KRT18 3875 Homo sapiens keratin 18 (KRT18) –4.71 0.15*
KRT5 3852 Homo sapiens keratin 5 (KRT5) –6.03 0.0023*
KRT6A 3853 Homo sapiens keratin 6A (KRT6A) –7.82 0.0031*
KRT8 3856 Homo sapiens keratin 8 (KRT8) –6.84 0.0051*
LTBP1 4052 Homo sapiens latent transforming growth factor –2.85 0.91
beta binding protein 1 (LTBP1)
TFPI 7035 Homo sapiens tissue factor pathway inhibitor –2.80 0.25
(lipoprotein-associated coagulation inhibitor) (TFPI)
TP63 8626 Homo sapiens tumor protein p63 (TP63) –208.88 0.32
*Minafra et al. (19).
Table III. Up-regulated genes in breast cancer primary culture.
Gene symbol Entrez Gene Description Microarray qRT-PCR 
ID Fold Change Fold Change
ACTA2 59 Homo sapiens actin, alpha 2, smooth muscle, aorta (ACTA2) 15.91 28*
CDH2 1000 Homo sapiens cadherin 2, type 1, N-cadherin (neuronal) (CDH2) 26.70 8.2*
COL6A3 1293 Homo sapiens collagen, type VI, alpha 3 (COL6A3) 80.06 >45
COL8A1 1295 collagen, type VIII, alpha 1 102.02 33
CTGF 1490 Homo sapiens connective tissue growth factor (CTGF) 79.57 42
CTSK 1513 Homo sapiens cathepsin K (CTSK) 113.77 7.4
FAP 2191 Homo sapiens fibroblast activation protein, alpha (FAP) 86.99 5.4
FGF2 2247 Homo sapiens fibroblast growth factor 2 (basic) (FGF2) 43.33 42
FN1 2335 Homo sapiens fibronectin 1 (FN1) 35.63 11*
FST 10468 Homo sapiens follistatin (FST) 42.98 7.9
ID2 3398 Homo sapiens inhibitor of DNA binding 2, dominant 16.42 44
negative helix-loop-helix protein (ID2)
IL6 3569 Homo sapiens interleukin 6 (interferon, beta 2) (IL6) 89.42 9.2
KRT19 3880 Homo sapiens keratin 19 (KRT19) 16.21 19.8
LOXL2 4017 Homo sapiens lysyl oxidase-like 2 (LOXL2) 24.29 11.44
MMP3 4314 Homo sapiens matrix metallopeptidase 3 117.57 9.4
(stromelysin 1, progelatinase) (MMP3)
MXRA5 25878 Homo sapiens matrix-remodelling associated 5 (MXRA5) 40.23 15.5
PDGFRB 5159 Homo sapiens platelet-derived growth factor receptor, 118.88 2.2
beta polypeptide (PDGFRB)
POSTN 10631 Homo sapiens periostin, osteoblast specific factor (POSTN) 281.80 35
TGFB1 7040 Homo sapiens transforming growth factor, beta 1 (TGFB1) 3.33 6.8*
THBS1 7057 Homo sapiens thrombospondin 1 (THBS1) 347.62 2.7
TWIST 7291 Homo sapiens twist homolog 1 (Drosophila) (TWIST1) 3.03 20.9*
VIM 7431 Homo sapiens vimentin (VIM) 9.68 36.5*
WNT5A 7474 Homo sapiens wingless-type MMTV integration 53.08 2.9
site family, member 5A (WNT5A)
*Minafra et al. (19).
characteristics and behaviour in vivo. Indeed, their application
in clinical research could represent a powerful system for
studying molecular mechanisms of human disease such as BC
in order to define individualized anticancer therapies in the
future. Recently, we described EMT in a primary cell culture
derived from a patient with breast IDC which revealed
phenotypic traits and expression of several mesenchymal
biomarkers. The EMT phenomenon is difficult to predict due
to its dynamic evolution inside tissues. Thus, the aim of the
present study was to analyze the gene expression profile by
cDNA microarray of BC cells from primary culture in order
to identify known and less well-known putative EMT markers
of BC. Indeed, a very limited number of reports describe gene
expression profile of EMT in BC cell lines (21-23, 35-36), and
to our knowledge, only one other study has examined EMT
transition in BC primary culture by microarray approach (24). 
Several bibliographical data are available concerning the
role of some of the selected genes in EMT transition such
as: ACTA2, CD24, CDH1, CDH2, CTSK, CTGF, FGF2,
FN1, ID2, IL6, KRT18, KRT8, LOXL2, MMP3, TP63,
POSTN, TGFB1, THBS1, TWIST, VIM and WNT5A. For this
reason, their functional role will be not discussed here. 
Conversely, no data or few are available on COL6A3,
COL8A1, AREG, ESRP2, FAP, PDGFRB, FST, LTBP1,
KRT19, KRT5, KRT6A, FBLN1, FGFBP1, MXRA5 and TFPI
genes in EMT. 
In the tumor microenvironment, both stromal and cancer
cells contribute along with various types of extracellular
matrix (ECM) proteins to actively remodel the
microenvironment and favour tumor growth and metastasis.
EMT provides a mechanism where cells adopt a motile
phenotype and, regarding this process, ECM proteins are
often described: for example increased collagen production
is linked with malignancy. Nevertheless, no one has
described the role of COL8A1 in EMT and only recent work
describes COL6A3 protein as being actively involved in
mammary tumour progression through enhancing EMT,
fibrosis and chemokine activity, thereby recruiting stromal
cells to the tumor microenvironment (37, 38). Both COL6A3
and COL8A1 were up-regulated in our study. Notably, all
these activities are associated with acquired drug resistance:
Park et al. suggest that this protein is a predictor of
chemoresistance to cisplatin in patients with solid tumors,
including BC, being able to enhance EMT. Thus, COL6A3
Minafra et al: cDNA Microarray Analysis of EMT in Primary Breast Cancer Culture
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Figure 2. STRING analysis of known and predicted protein interactions existing among the 36 selected genes closely connected in a single network.
has been highlighted as a promising candidate triggering
drug resistance against platinum-based therapeutics, since its
levels are vastly increased in cisplatin-resistant cancer cells
in vitro. However, the detailed molecular mechanisms
underlying these correlations remain elusive (39).
AREG, or amphiregulin protein, is an EGF receptor
ligand, essential for in vitro proliferation of human
keratinocytes under autocrine and growth factor-stimulated
conditions (40). AREG was recently described by Yang et al.
to be able to mediate EGF-independent growth and
malignant behaviour of mammary epithelial cells in a non-
cell-autonomous manner. It is a target for a transcriptional
co-activator named TAZ factor having a PDZ-binding motif,
which in human mammary epithelial cells promotes EMT,
but no additional data are available on this topic. Positive
correlation between TAZ and AREG proteins in a patient
with BC was revealed in vivo. Of particular note, AREG can
be secreted into the blood system, and its detection would be
non-invasive and quite simple (41, 42).
To date, the epithelial splicing regulatory proteins (ESRPs)
are the only known splicing factors that exhibit epithelial
cell-type-specific expression and that undergo pronounced
changes in expression during the EMT. A loss of ESRP2
expression is a generalized event during the EMT, and was
shown by studies in which the induction of EMT by TGFB1,
SNAIL, ZEB1, ZEB2, and E-cadherin knockdown was
accompanied by a nearly complete abrogation of ESRP
expression (22, 43, 44). Cells lacking ESRP1 and ESRP2
lost cell–cell adhesion, acquired a stellate-like shape, and
became more motile. Changes in cell morphology and
ANTICANCER RESEARCH 34: 2173-2184 (2014)
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Figure 3. Analysis of the most significant Gene Ontology biological processes highlighted in the STRING network.
behaviour through abrogation of an epithelial splicing
program suggests that the ESRPs regulate transcripts that,
while expressed in both epithelial and mesenchymal cells,
encode protein isoforms with unique functions specific to
each cell type. For these reasons Warzecha and Carstens
suggest a model whereby the ESRPs are master regulators of
epithelial cell function and morphology (45). Interestly, only
two articles describe the relation between ESRPs and BC,
showing their down-regulation after EMT (TGFB-induced)
during BC progression (46-49), in line with our data.
During EMT, tumor cells interact with activated stromal
fibroblasts, also known as cancer-associated fibroblasts, in
order to define tumour phenotype development. Quiescent
fibroblasts become activated through mutual paracrine effects
with tumour cells. Some differentially expressed markers of
cancer-associated fibroblasts, including fibroblast activation
protein (FAP or seprase) and PDGFRB, were up regulated in
BC primary culture cells. Although an influence of these
markers on EMT is postulated, their functional importance
for modulation of cancer cell phenotype is not fully
understood (49, 50).
Currently, no data regarding EMT and FST, LTBP1,
KRT19, KRT5, KRT6A, FGFBP1 and TFPI, are available, but
a relation between these factors and BC was described. Thus,
they could represent new markers of EMT in BC.
In addition, scarce information exists for FBLN1 or
MXRA5 genes and EMT or BC. FBLN1 is a secreted
glycoprotein that becomes incorporated into a fibrillar
extracellular matrix and has been indicated as a prognostic
marker for near-term events (2.5 years) for both patients with
lymph node-positive and those with lymph node-negative BC
(51). Moreover, MXRA5 gene, which encodes for one of the
matrix-remodelling associated proteins, has been recently
described as a new cancer gene, frequently mutated in non-
small cell lung carcinoma (52) and by us described for the
first time in EMT and BC. Further analysis should clarify
their role on this matter.
Concluding, gene expression data for BC cells of primary
culture are in line with those reported in literature concerning
EMT in cancer cells, with special focus on BC. In the
present work we describe the involvement of novel genes
able to guide this process, highlighting a molecular network
that could contribute to the control of EMT. EMT markers
identified here should act as prognostic indicators, for
example in response to drug therapies or to ionizing radiation
treatments, in which this transition may play a key role not
yet well-known (53, 54). 
Conclusion
Our gene expression data show the involvement of novel
genes which display tight relationships among them,
suggesting a molecular network in which they could
contribute to regulation of EMT in BC. We trust that this
study may offer a further basis for understanding the
complex mechanisms which regulate BC progression, such
as the EMT, and for designing individualized anticancer
therapies in the future. 
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